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Abstract
Mucopolysaccharide diseases (MPS) are caused by deficiency of glycosaminoglycan (GAG) degrading enzymes, leading to
GAG accumulation. Neurodegenerative MPS diseases exhibit cognitive decline, behavioural problems and shortened
lifespan. We have characterised neuropathological changes in mouse models of MPSI, IIIA and IIIB to provide a better
understanding of these events. Wild-type (WT), MPSI, IIIA and IIIB mouse brains were analysed at 4 and 9 months of age.
Quantitative immunohistochemistry showed significantly increased lysosomal compartment, GM2 ganglioside storage,
neuroinflammation, decreased and mislocalised synaptic vesicle associated membrane protein, (VAMP2), and decreased
post-synaptic protein, Homer-1, in layers II/III-VI of the primary motor, somatosensory and parietal cortex. Total heparan
sulphate (HS), was significantly elevated, and abnormally N-, 6-O and 2-O sulphated compared to WT, potentially altering
HS-dependent cellular functions. Neuroinflammation was confirmed by significantly increased MCP-1, MIP-1a, IL-1a, using
cytometric bead arrays. An overall genotype effect was seen in all parameters tested except for synaptophysin staining,
neuronal cell number and cortical thickness which were not significantly different from WT. MPSIIIA and IIIB showed
significantly more pronounced pathology than MPSI in lysosomal storage, astrocytosis, microgliosis and the percentage of
2-O sulphation of HS. We also observed significant time progression of all genotypes from 4–9 months in lysosomal storage,
astrocytosis, microgliosis and synaptic disorganisation but not GM2 gangliosidosis. Individual genotype*time differences
were disparate, with significant progression from 4 to 9 months only seen for MPSIIIB with lysosomal storage, MPSI with
astrocytocis and MPSIIIA with microgliosis as well as neuronal loss. Transmission electron microscopy of MPS brains revealed
dystrophic axons, axonal storage, and extensive lipid and lysosomal storage. These data lend novel insight to MPS
neuropathology, suggesting that MPSIIIA and IIIB have more pronounced neuropathology than MPSI, yet all are still
progressive, at least in some aspects of neuropathology, from 4–9 months.
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Introduction
The series of pathogenic events that cause severe neurodegen-
eration and ultimately death in the mucopolysaccharide (MPS)
diseases is still not fully understood. Amongst this complex set of
diseases, MPSI (Hurler), IIIA and IIIB (Sanfilippo) are inherited
neurodegenerative lysosomal storage disorders (LSD) caused by
deficiency of the glycosaminoglycan (GAG) degrading enzymes a-
iduronidase (IDUA), N-sulphoglucosamine sulphohydrolase
(SGSH) or a-N-acetylglucosaminidase (NAGLU) respectively. This
deficiency leads to storage of GAGs in all cells of the body causing
multisystem disease, with specific phenotypes exhibited depending
upon the type of GAG stored. In addition to peripheral disease
such as organomegaly, cardiac and respiratory insufficiency, there
are MPS sub-types that store dermatan sulphate and chondroitin
sulphate and exhibit bone and joint disease (eg MPSI, II, IV, VI
and VII), whereas those that store heparan sulphate (HS; eg
MPSI, II, III and VII) show severe progressive neurodegeneration
[1,2]. MPSI Scheie, an attenuated non-neuropathic form of MPSI,
can be treated using enzyme replacement therapy (ERT).
However, patients with a more severe neuropathic form, (MPSI
Hurler), require a haematopoietic stem cell transplant (HSCT)
where donor-derived cells are able to traffic across the blood-brain
barrier and cross-correct cells in the brain. MPSIII patients
present with severe behavioural changes such as aggression,
hyperactivity and disrupted sleep [3,4] but HSCT does not
ameliorate the brain disease and ERT is unlikely to cross the
blood-brain barrier [5,6]. Substrate reduction therapy (SRT),
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using high doses of the isoflavone genistein aglycone, has shown
very promising results in a mouse model of MPSIIIB [7,8].
Accumulation of excess HS has the potential to influence many
downstream events since this GAG plays a major role in a number
of critical processes in the body. HS is essential during
development and adult life, where it has a role in the regulation
of various crucial signalling pathways by interacting with
molecules such as growth factors and morphogens, as well as
being an important component of the extracellular matrix
[9,10,11,12]. HS structure is often changed during disease,
whereby its altered binding properties act to exacerbate the
disease phenotype [13,14]. HS is composed of alternate repeating
units of glucosamine (GlcN) and uronic acid (glucuronic acid
[GlcA] or iduronic acid [IdoA]), which can be variably sulphated
at the N-, 6-O- and rarely 3-O-position of glucosamine and/or 2-O-
position of uronic acid (NS, 6S, 3S and 2S). These sulphate groups
are added in small clusters (sulphated domains), separated by
regions with no or little modification (N-acetylated- [NAc2])
domains, with the positioning of sulphate groups ultimately
dictating biological function. For example, 6-O- and 2-O-sulphate
groups are essential for the formation and signalling of active
fibroblast growth factor/fibroblast growth factor receptor com-
plexes [15], and 2-O sulphated HS is also important in HS:SDF-1
(stromal cell derived factor-1) interaction and signalling [16].
Recently we have shown elevated levels of N-, 2-O- and 6-O-
sulphated HS in MPSI mouse brain using reverse-phase HPLC
separation of AMAC-derivatised disaccharides [17]. Increased N-
sulphated disaccharides have been detected in MPSIIIA mouse
brain [18] and 2-O-sulphated HS in MPSI and IIIA patient urine
and serum [19,20] using tandem mass spectrometry.
Mouse models of MPSI and III can be used to test various
treatment strategies and to facilitate the understanding of the
neurological pathology involved at various stages. It has been
shown that MPSI, IIIA and IIIB mouse brains exhibit primary
storage of HS, secondary accumulation of GM2 and 3 gangliosides
and severe neuroinflammation [6,21,22,23,24,25], but these
parameters have never been fully quantified so that direct
comparisons could be made between these three sub-types in
detail. Changes in the level of synaptic proteins, vesicle associated
membrane protein 2 (VAMP2 or synaptobrevin 2) and synapto-
physin, have been observed in MPSIIIB mice, which may result in
altered downstream synaptic signalling events [8,26,27], but this
has not been shown for MPSI and MPSIIIA. Alterations in the
levels of synaptic proteins may result in behavioural changes and
ultimately neurodegeneration.
The aim of this study was to examine, compare and fully
quantify various neuropathological phenotypes in the brains of
MPSI, IIIA and IIIB mice to establish the events that lead to
neurodegeneration and provide additional outcome measures for
MPS treatment strategies. Brains from mice aged between 4 and
9 months were analysed since we have noted behavioural changes
over this time frame [27,28]. This was achieved by quantitative
immunohistochemical analysis for lysosomal compartment size,
secondary storage of GM2 ganglioside, neuroinflammation, the
synaptic proteins VAMP2, synaptophysin and Homer-1, mea-
surements of cerebral cortical thickness, neuronal cell number
and transmission electron microscopy (TEM). Biochemical
analysis and quantification of HS amounts and HS sulphation
patterning in MPS brain were also analysed, which have not been
shown previously for MPSIIIA and IIIB mouse brains. We found
that MPSI, IIIA and IIIB mouse brains had extensive primary
and secondary storage, as well as significant neuroinflammation,
with a loss of organisation of synaptic vesicle membrane protein
VAMP2, a reduction in the post-synaptic protein Homer-1 but
no change in synaptophysin levels and no decrease in cerebral
cortical thickness or overall change in neuronal cell number.
Elevated levels of HS were present in MPS brains compared to
WT. More importantly, this HS was found to be abnormal, being
heavily sulphated along its length, which is likely to alter its
biological function. This may provide an insight into under-
standing the neuropathogenic events that drive severe neurode-
generation and ultimately death.
Results
Lysosomal compartment size becomes progressively
larger in brains from MPSI, MPSIIIA to MPSIIIB mice
Quantification of LAMP2 (lysosomal associated membrane
protein) immunoreactivity from 2 fields of view each from 4
sections per mouse (Figure 1A) was used to compare the size of
the lysosomal compartment in the primary motor, somatosensory
and parietal areas of the cerebral cortex in WT, MPSI, IIIA and
IIIB at 4 and 9 months of age. LAMP2 immunoreactivity
exhibited an intense vesicular staining pattern that was more
intense in MPS brain than WT (Figure 1B, C and D). Two way
ANOVA for genotype versus time revealed a significant genotype
effect, with LAMP2 staining in MPSIIIB significantly increased
over MPSIIIA (p,0.001), MPSI (p,0.001) and WT (p,0.001),
MPSIIIA significantly increased over both MPSI (p,0.03) and
WT (p,0.001) and MPSI significantly increased over WT
(p,0.001; Figure 1C). There was also a significant overall time
effect, with 9 months LAMP2 staining more intense than 4
months (p,0.001). However, the genotype*time interaction was
also significant (p,0.01) suggesting that different genotypes
change differentially over time. Where significant genotype*time
effects were seen, we established that WT was the genotype
behaving differently to the MPS genotypes by performing a
confirmatory 2 way ANOVA on time vs genotype for MPS
genotypes alone. This allowed us to confirm that MPS genotypes
all progress over time for LAMP2. When multiple comparisons
were made between all genotypes at all times, (green lines), each
WT group had significantly less LAMP2 staining than any MPS
group (p,0.001; not shown on figure). In MPSIIIB brains, the
lysosomal compartment became progressively larger from 4
months to 9 months (p,0.001; Figure 1C) and was also
significantly larger than both MPSI and IIIA at 4 (p,0.01) and
9 months of age (p,0.001; Figure 1C).
In all other regions of MPS brain, LAMP2 staining was much
more intense than in WT and was observed in various cell types in
MPSI, IIIA and IIIB. Confocal microscopy at a higher
magnification confirmed our observations and showed an enlarged
lysosomal compartment (LAMP2) in both neurons (neuronal
nuclei; NeuN) and in microglia (Isolectin B4; ILB4) in layer II/III
as shown in representative sections of MPSI, IIIA and IIIB
cerebral cortex (Figure 1D; Single colours and overlays are shown
in Figure S1).
Transmission electron microscopy (TEM) revealed an increase
in lysosomal storage burden in the cells of the cerebral cortex in
MPS brain compared to WT (black arrows outlined in white;
Figure 2A–D, F). Most of the lysosomes also exhibited lipid storage
as shown in Figure 2A–D (white arrows outlined in black). MPS
brain cells also contained many more vacuoles and the cytoplasm
appeared to be denser than that observed in WTs. In addition,
dystrophic axons that contained storage material were observed in
MPSIIIB cerebral cortex (Figure 2G and H) at a much greater
frequency than in MPSI (Figure 2E), but were not detected in any
of the MPSIIIA brain sections examined (n= 3 per group;
Figure 2F). These dystrophic axons contained multiple vesicular
MPSI, IIIA and IIIB Neuropathology
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Figure 1. Lysosomal compartment size is significantly increased in MPS brain and localises to neurons and microglia. Lysosomal
compartment size was measured by quantifying LAMP2 immunohistochemical staining of WT, MPSI, IIIA and IIIB mouse cerebral cortex at 4 and 9
months of age (4 m and 9 m; n = 3 mice per group). (A) Four sections of brain from Bregma 0.26, 20.46 21.18 and 21.94 mm were stained
concurrently. (B) Representative sections stained with LAMP2 that correspond to a whole field of view covering cortical layers II/III–VI (Section 2a in A).
Bars = 100 mm. (C) Two fields of view (boxed areas in A;620 objective) from each section were quantified using ImageJ. Error bars represent the SEM
and p values are from two way ANOVA with Tukey’s multiple comparisons test. Significant overall genotype differences are denoted by thick black
lines. Individual genotype*time differences are shown by thin green lines. The significant individual genotype*time differences (p,0.001) between all
MPSs and WT at each time point are not shown for clarity. (D) LAMP2 (green) was detected in NeuN-positive neurons (red) and in ILB4-positive
microglia (red) in layer II/III of WT, MPSI, IIIA and IIIB cerebral cortex. Nuclei are stained with DAPI (blue); Bar = 10 mm. Single colours and overlays are
shown in Figure S1.
doi:10.1371/journal.pone.0035787.g001
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organelles, some of which exhibited very electron dense material,
were similar to immature and mature autophagosomes, and some
also contained mitochondria (denoted by* in Figure 2E and H).
Notably, the thickness of myelination in these dystrophic axons
was substantially reduced compared to WT. All MPS types also
exhibited normal axons (Figure 2E–G; arrow heads).
MPSI, IIIA and IIIB brains exhibited a significant increase
in the amount and level of sulphation of HS
disaccharides compared to WT
To investigate the accumulation and structure of stored HS
GAGs, HS chains were purified from WT, MPSI, IIIA and IIIB
mouse brain tissue (1 hemisphere per mouse at 9 months of age)
and completely depolymerised into their component disaccharides
using bacterial heparinase enzymes. Reverse-phase HPLC sepa-
Figure 2. Transmission electron microscopic analysis of MPS brain showing an increase in lysosomal burden in MPS cerebral cortex
and large dystrophic axons in MPSI and IIIB. Images show an increase in lysosomal burden (black arrows outlined in white) in MPSI, IIIA and IIIB
(B–D and F; Bars = 1 mm) compared to WT cerebral cortex (A; Bar = 1 mm). Lipid (white arrows outlined in black) is also stored in the lysosomes of MPS
brain (B, C, and D) and also a small amount in WT (A). Dystrophic axons were observed in MPSI (E; Bar = 0.5 mm) and IIIB (arrow in G; Bar = 1 mm and
enlarged in H; Bar = 0.5 mm) cerebral cortex but not in MPS IIIA (F; Bar = 1 mm). These structures contained organelles similar to immature and mature
autophagosomes with electron dense material and some mitochondria (*; E and H). Normal axons were also observed in all MPS types (E, F and G;
arrow heads).
doi:10.1371/journal.pone.0035787.g002
MPSI, IIIA and IIIB Neuropathology
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ration of AMAC-derivatised disaccharides was then used to
quantify the amounts and type of sulphation patterns in each HS
type, using integration analysis of peak area to enable quantifica-
tion.
HS composition analysis revealed that all three MPS types,
exhibited significantly increased levels of tri-sulphated disaccharide
HexA(2S)-GlcNS(6S) (where HexA is GlcA or IdoA), typically
confined to the most highly sulphated domains within HS,
compared to WT (p,0.001) by 2.5, 2.9 and 3.2 fold respectively
(Figure 3A). There was also a significant increase in these tri-
sulphated disaccharides in MPSIIIB compared to MPSI (p,0.04),
but not between MPSI and IIIA or IIIA and IIIB (Figure 3A). A
similar result was also observed for HexA(2S)-GlcNS (Figure 3A)
with MPS brain exhibiting significantly increased levels compared
to WT (p,0.001) by around 2 to 2.4 fold. A significant increase in
HexA(2S)-GlcNS in MPSIIIB compared to MPSI (p,0.001) and
MPSIIIA compared to MPSI (p = 0.01) was also visible, but was
not seen between MPSIIIA and IIIB.
As expected, the opposite effect was observed with mono-
sulphated or non-sulphated HS disaccharides, with a significant
decrease in the levels of HexA-GlcNS and HexA-GlcNAc
disaccharides in MPSI, IIIA and IIIB compared to WT
(p,0.001; Figure 3A), with a significant reduction in HexA-
GlcNS (p,0.003) and HexA-GlcNAc (p,0.006) from MPSI to
IIIB, but not between MPSI and IIIA or between IIIA and IIIB. A
significant reduction in the level of HexA-GlcNS(6S) was only
observed between WT and MPSIIIA (p,0.04) and in HexA-
GlcNAc(6S) between WT and MPSIIIA (p,0.03) and IIIB
(p,0.001).
Comparing the overall levels of particular HS modifications (by
calculating the percentage of total disaccharides containing either
GlcNAc or GlcNS, or 2S or 6S groups) highlighted the significant
increase in NS, 6S and 2S modification of HS in MPSI, IIIA and
IIIB brain (p,0.001) compared to WT, with a general trend of
increasing levels of all types of sulphation modification from MPS I
through to IIIA then IIIB (Figure 3B). This was reflected by a
significant reduction in unmodified NAc containing disaccharides
compared to WT (p,0.001; Figure 3B). No significant differences
were observed between MPSI and IIIA, but a significant reduction
was found between MPSI and IIIB (p,0.001) and MPSIIIA and
IIIB (p,0.02). The most significantly increased modification was
in 2S. In WT brain only 20% of the total disaccharides in the HS
chain were modified by the addition of a 2S group. However this
increased to 44% in MPSI, 52% in IIIA and 56% in IIIB.
Significant differences were observed between MPSI and IIIA
(p = 0.01) and MPSI and IIIB (p,0.001). 2S is typically restricted
to sulphated domains, implying large increases in either the
number or length of sulphated domains within the HS chain.
This method of analysis also enabled the relative levels of total
HS to be compared quantitatively between WT and MPS types
[29]. Compared to WT, a significant 15.5-fold increase in the
amount of HS was apparent in MPSI mice, increasing to,26-fold
in MPSIIIA (Figure 3C). Interestingly, although levels of HS were
markedly increased in MPSIIIB compared to WT by ,5.5-fold
(p,0.02), this increase was significantly less than amounts seen in
MPSI and MPSIIIA (p,0.02). This suggests that despite the fact
the HS in MPSIIIB mice is abnormally highly sulphated, less is
stored in the brain than the other MPS types.
A significant amount of secondary storage of
gangliosides occurs by 4 months of age in MPSI, IIIA and
IIIB mouse brains
To reveal the secondary storage of accumulated GM2
gangliosides in MPS brain, GM2 ganglioside immunoreactivity
was performed and quantified across layer II to V/VI of the
primary motor, somatosensory and parietal areas of the cerebral
cortex, as shown in the low power images in Figure 1A (8 fields of
view per mouse; n= 3). GM2 ganglioside immunoreactivity in
MPS mice exhibited an intense vesicular staining pattern in layers
II/III and V/VI of the cerebral cortex with less staining in layer
IV and was negligible in WT (Figure 4A [low power of layers II/
III to VI and high power of layer II/III]). Two way ANOVA for
genotype versus time revealed a significant genotype effect with
GM2 ganglioside staining in MPS brain significantly increased
over WT (p,0.001). There were no significant differences
between the MPS genotypes and no overall time effect
(Figure 4A and B).
Intense GM2 staining was also found in other areas of MPS
brain in addition to the cerebral cortex, with extremely intense
GM2 immunoreactivity readily observable at low magnification
(Figure 4C) and was consistent between the three MPS types. As
stated above, negligible staining was seen in the WT brain (data
not shown). Very intense GM2-immunoreactivity was observed in
the following structures; secondary motor cortex (M2), amygdala
(A), lateral septal nucleus (LSi), stria terminalis (ST), preoptic area
(PO), ventral pallidum (VP), interstitial nucleus of the posterior
limb of the anterior commisure (IPAC), retrosplenial granular
cortex (RSD), hypothalamic (HA) areas and the pyramidal cells of
the hippocampus (Pyr); with relatively less intense staining in the
cingulum (cg), thalamic area (Rt) and globus pallidus (GP),
(Figure 4C).
MPSI, IIIA and IIIB mouse models exhibit chronic
neuroinflammation
Astrocyte activation was assessed by counting the number of
GFAP-positive astrocytes from 8 fields of view per mouse (n = 3)
from the primary motor, somatosensory and parietal areas of the
cerebral cortex as shown in Figure 1A. Two way ANOVA for
genotype versus time revealed a significant overall genotype effect
with astrocyte activation in MPSIIIB and IIIA significantly
increased over MPSI (p,0.04) and WT (p,0.001), and all MPS
genotypes were significantly increased over WT (p,0.001;
Figure 5A and B). There was also a significant overall time effect,
with 9 months astrocyte activation higher than 4 months
(p,0.001). However, the genotype*time interaction was also
significant (p,0.01) suggesting that different genotypes change
differentially over time. Where significant genotype*time effects
were seen, we established that WT was the genotype behaving
differently to the MPS genotypes by performing a confirmatory 2
way ANOVA on time vs genotype for MPS genotypes alone. This
allowed us to confirm that MPS genotypes all progress over time
for GFAP.
When multiple comparisons were made between all genotypes
at all times (green lines), each WT group had significantly fewer
reactive astrocytes than any MPS group (p,0.001; not shown on
figure). Astrocyte activation in MPSI increased from 4 months to 9
months of age (p,0.0005; Figure 5B), and was lower at 4 months
compared to MPSIIIA and IIIB (p,0.001). However no
significant differences were seen in the level of astrocyte activation
between any MPS types at 9 months. In other regions of WT
brain, fibrous astrocytes were found in and along the corpus
callosum, optic chiasm and along the third ventricle and
hippocampus, but only very few palely stained protoplasmic
astrocytes were found scattered throughout the cerebral cortex
(data not shown). However, in MPS brains, astrocytes were much
greater in number throughout each whole section of the brain
examined.
MPSI, IIIA and IIIB Neuropathology
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Similarly, isolectin B4-positive cells were counted in the same
areas to determine the level of microglial activation (Figure 5C and
D) in the primary motor, somatosensory and parietal areas of the
cerebral cortex as shown in Figure 1A. Two way ANOVA for
genotype versus time revealed a significant genotype effect with
microglial activation in MPSIIIB and IIIA, significantly increased
over both MPSI (p,0.001) and WT (p,0.001), and MPSI was
significantly increased over WT (p,0.001; Figure 5C and D).
There was also a significant overall time effect, with 9 months
microglial activation higher than 4 months (p,0.001).
When multiple comparisons were made between all genotypes
at all times (green lines), each WT group had significantly fewer
microglia than any MPS group (p,0.001). MPSI brain exhibited
significantly less microglial activation than both MPSIIIA and IIIB
at each time point (p,0.05) with no significant differences between
MPSIIIA and IIIB at either time point. Microglial activation in
MPSIIIA was found to significantly increase over time (p,0.005;
Figure 5D).
Very few isolectin B4-stained microglial cells were found in
these areas of WT brains, with only 1 or 2 cells detected per field
of view in the cerebral cortex and optic chiasm, otherwise the
sections contained no positively stained microglia (Figure 5C and
E). In contrast, in MPS brains, microglia were much larger and
evenly distributed across the entire brain section (sections 1–4;
Figure 5E, representative low power images for MPSIIIA) at a
density similar to that observed in the cerebral cortex (Figure 5C)
with a limited number in the lateral preoptic area. Examples of
whole fields of view corresponding to section 2a that were used for
counting are included in Figure S2 and S3 for GFAP and ILB4
respectively.
Cytometric bead array analysis (CBA) was used to quantify a set
of inflammatory cytokines isolated from extracts of whole brain
Figure 3. Significant increases in the amount and sulphation of HS in MPS brains. (A) Compositional disaccharide analysis of HS from WT,
MPSI, MPSIIIA and MPSIIIB brains. (B) N-acetlylation, N-, 6-O-, and 2-O-sulphate distribution within HS isolated from WT, MPSI, MPSIIIA and MPSIIIB
brains. Values are calculated from the disaccharide analyses shown in A, specifying the percentage of total disaccharides along the HS chain that
contain each modification. (C) Total relative amounts of HS. * denotes where all groups were significantly different from each other. n = 3 mice per
group, error bars represent the SEM and p values are from one way ANOVA with Tukey’s multiple comparisons test.
doi:10.1371/journal.pone.0035787.g003
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Figure 4. Secondary storage of GM2 gangliosides in MPS mouse brain. (A) Representative images of low (cerebral cortical layers II/III–VI) and
high power sections (cerebral cortical layers II/III) of GM2 ganglioside stained sections at 9 months of age (9 m). Bars = 100 mm. (B) Four sections of
brain (Bregma 0.14, 20.58, 21.34, 22.2 mm) were stained concurrently for GM2 gangliosides and images of two low power (620 objective) fields of
view covering cortical layers II/III–VI (boxed areas, Figure 1A; whole field of view of section 2a is shown in Figure 4A low power) were captured from
MPSI, IIIA and IIIB Neuropathology
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from WT, MPSI, IIIA and IIIB mice at 8–9 months of age (n = 5–
6 per group) to further quantify the level of neuroinflammation in
MPS. Significant increases of monocyte chemoattractant protein
(MCP-1/CCL2; p,0.001), macrophage inflammatory protein
(MIP-1a/CCL3; p,0.01) and interleukin-1a (IL-1a; p,0.03)
were detected in brains of MPSI, IIIA and IIIB compared to WT
(Figure 6A, B and C). Furthermore, MPSIIIA brain exhibited
significantly higher levels of MIP-1a compared to MPSI brain
(p = 0.05) and MPSIIIB brain exhibited almost significantly higher
levels of MIP-1a compared to MPSI brain (p = 0.06; Figure 6B).
MPSIIIB brain showed significantly elevated KC/CXCL1
levels compared to WT and IIIA (p,0.05), but no differences
were observed between WT, MPSI and IIIA brains (Figure 6D).
No significant differences in the level of IL-6 was found between
WT and MPSI, IIIA and IIIB brain, although there was a trend
towards less IL-6 in MPSI, IIIA and IIIB compared to WT
(Figure 6E). MPSIIIB brain demonstrated significantly higher
levels of G-CSF (granulocyte colony stimulatory factor) compared
to WT but no significant differences were found between WT and
MPSI or IIIA or between MPSI, IIIA and IIIB. However there
was a trend towards an increase from WT to MPSI, IIIA with IIIB
mice exhibiting the highest amount (Figure 6F). The levels of
IFNc, IL-1b, IL-3, IL -9, IL-13 and GM-CSF (granulocyte
macrophage colony stimulatory factor) were below the level of
detection in WT, MPSI, IIIA or IIIB brains using this assay (data
not shown).
No changes in cerebral cortical thickness and neuronal
loss in MPS mouse brain
Two measurements of cortical thickness were taken from each
brain section (8 measurements per mouse). The first was from the
apex of the cingulum of the corpus callosum to the outside of
cerebral cortical layer II and the second was taken 1000 mm
laterally from the apex of the cingulum, from the corpus callosum
to the outside of cerebral cortical layer II. No significant genotype
or time differences were found between the cortical thickness of
WT and MPS mice (Figure 7A and C; white lines). Nissl-stained
cells were also counted in the primary motor, somatosensory and
parietal areas of the cerebral cortex, as shown in Figure 1A and
7A and B. Although no overall significant differences were found
in neuronal cell numbers between WTs and MPS types, there was
a significant genotype*time effect (p,0.009) with a significant
reduction in MPSIIIA from 4 to 9 months (p,0.05) (Figure 7D).
Given no significant difference to WT, this result should be treated
with caution.
Alteration of the synaptic proteins, VAMP2 and Homer-1
in MPSI, IIIA and IIIB mouse models
To determine if there was any evidence for synaptic pathology
in MPS brains, immunostaining for pre-synaptic vesicle mem-
brane proteins which are involved in the formation of the SNAP/
SNARE complex, VAMP2 and synaptopysin, were quantified.
VAMP2 exhibited a very distinct vesicular punctate staining in
WT cerebral cortex (Figure 8A). However, in MPS cerebral
cortex, this punctate staining was lost and was much more diffuse
(Figure 8A). VAMP2 staining was quantified in the primary motor,
somatosensory and parietal areas of the cerebral cortex (Figure 1A
and 8B). Two way ANOVA for genotype versus time revealed a
significant genotype effect with VAMP2 staining in MPS brain
significantly decreased over WT (p,0.001; Figure 8B). There was
a significant overall time effect, with 9 months VAMP2 staining
less intense than 4 months (p,0.01). There were no significant
differences between the MPS genotypes. The genotype*time
interaction was also significant (p = 0.04) suggesting that different
genotypes change differentially over time. Where significant
genotype*time effects were seen, we established that WT was the
genotype behaving differently to the MPS genotypes by perform-
ing a confirmatory 2 way ANOVA on time vs genotype for MPS
genotypes alone. This allowed us to confirm that MPS genotypes
all progress over time for VAMP2. When multiple comparisons
were made between all genotypes at all times (green lines),
VAMP2 staining was found to be significantly reduced in all MPS
groups compared to WT groups (p,0.001; not shown on figure).
No significant differences were found in immunoreactivity for
VAMP2, between MPSs at either time point, but VAMP2 staining
was found to have decreased over time in MPSIIIA (p,0.02);
Figure 8B). This relative loss of punctate VAMP2 staining was
detected throughout the MPS brain sections examined. Synapto-
physin staining was also quantified in the primary motor,
somatosensory and parietal areas of the cerebral cortex, but no
significant differences were observed between WT and MPS
brains at either time point (Figure 8C), suggesting that the altered
VAMP2 staining represents a rearrangement of the pre-synaptic
compartment rather than an overt loss of synapses.
Homer-1, a protein enriched at the post-synaptic density of
excitatory synapses, exhibited a much more diffuse pattern of
staining compared to VAMP2 (Figure 8D). Quantification of
Homer-1 staining in the primary motor, somatosensory and
parietal areas of the cerebral cortex (Figure 1A) showed that it was
significantly reduced in MPS brain compared to WTs (p,0.02;
Figure 8E). No significant differences were found in immunore-
activity for Homer-1 between MPSs at either time point (data
unavailable for MPSIIIB at 4 months). This suggests that signalling
at the post-synaptic density may also be altered.
Discussion
Our data directly compares the severity of neuropathology in
terms of primary and secondary storage material, neuroinflamma-
tion and the level of two pre-synaptic vesicle proteins and a post-
synaptic protein in mouse models of MPSI, IIIA and IIIB. The
progression of brain pathology was analysed between 4 and 9
months of age as we have noted behavioural changes over this
time frame [27,28]. The complete set of comparative neuropa-
thology results are summarised in Table 1.
The lysosomal compartment became progressively larger in
MPSI, MPSIIIA and MPSIIIB mouse brains and was significantly
different in each case. The difference between MPSIIIA and IIIB
may be due in part to the MPSIIIA mouse model retaining around
3–4% of normal SGSH enzyme activity [22], thus it could be a
more attenuated model. An enlarged lysosomal compartment has
been observed previously in separate studies using mouse models
of MPSI [25], MPSIIIA [30] and MPSIIIB [7,8,25,27], but they
each section and quantified using ImageJ (n = 3 mice per group). Error bars represent the SEM and p values are from two way ANOVA with Tukey’s
multiple comparisons test. Significant overall genotype differences are denoted by thick black lines. (C) Low power plans (62.5 objective) of
representative sections of a brain analysed from each group, showing the location of the very intense GM2 immunoreactivity. These areas are labelled
as secondary motor cortex (M2), amygdala (A), cingulum (cg), lateral septal nucleus (LSi), stria terminalis (ST), preoptic area (PO), ventral pallidum (VP),
globus pallidus (GP), interstitial nucleus of the posterior limb of the anterior commisure (IPAC), retrosplenial granular cortex (RSD), thalamic (Rt) and
hypothalamic (HA) areas and pyramidal cells of the hippocampus (Py). Bar = 100 mm.
doi:10.1371/journal.pone.0035787.g004
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Figure 5. Significant neuroinflammation in MPS cerebral cortex at 4 and 9 months of age. Representative sections of positively stained (A)
astrocytes (GFAP; brown) and (C) microglia (Isolectin B4:brown) at 4 and 9 months of age (4 m and 9 m) that correspond to a high power view
covering cortical layer IV (from section 2a, Figure 1A). Boxed inserts show an enlarged single positively stained astrocyte or microglial cell. Sections
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were counterstained with Mayer’s haematoxylin to highlight the nuclei. Bar = 100 mm. Whole fields of view used for counting are shown in Figures S2
and S3. Four sections of brain were stained concurrently with either GFAP or Isolectin B4, and images of two low power fields of view covering
cortical layers II/III–VI (boxed areas, Figure 1A) were captured from each section. The number of GFAP or Isolectin B4 positive cells in these areas were
counted using ImageJ and expressed as an average number of cells per section (B and D respectively; n = 3 mice per group). Error bars represent the
SEM and p values are from two way ANOVA with Tukey’s multiple comparisons test. Significant overall genotype differences are denoted by thick
black lines. Individual genotype*time differences are shown by thin green lines. The significant individual genotype*time differences (p,0.001)
between all MPSs and WT at each time point are not shown for clarity. (E) Low power plans (62.5 objective) showing 4 representative brain sections
from WT and MPS IIIA mice stained with Isolectin B4. Sections from MPSI and MPSIIIB are not shown but are virtually identical in distribution and
intensity. Bar = 100 mm.
doi:10.1371/journal.pone.0035787.g005
Figure 6. Elevated inflammatory cytokines in MPS at 9 months of age. WT, MPSI, IIIA and IIIB mouse brains were analysed using cytometric
bead array analysis to quantify a set of inflammatory cytokines isolated from whole extracts to further quantify the level of neuroinflammation in MPS
(A) MCP-1, (B) MIP-1a (C) IL-1a, (D), KC (E) IL-6 and (F) G-CSF. IFNc, IL-1b, IL-3, IL -9, IL-13 and GM-CSF were below the level of detection using this
assay. n = 5–6 mice per group, error bars represent the SEM and p values are from one way ANOVA with Tukey’s multiple comparisons test.
doi:10.1371/journal.pone.0035787.g006
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Figure 7. No significant changes in the cortical thickness or Nissl positive cell number. (A) Cerebral cortical thickness was measured from
the apex of the cingulum of the corpus callosum to the outside of cerebral cortical layer II. A second measurement was taken 1000 mm laterally from
the apex of the cingulum, from the corpus callosum to the outside of cerebral cortical layer II. These measurements (white lines in A) were taken from
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have not been compared directly with each other in one
comprehensive fully quantified study. Interestingly we also
observed an overall progression in lysosomal size from 4 to 9
months in all genotypes despite the presence of the WT which
does not change with time. The skewing effect of the WT probably
explains the significant genotype*time effect that we observed –
which indicates that some genotypes follow a different progression
to others. To establish this we also performed 2 way ANOVA on
time vs genotype for MPS genotypes alone, which also confirmed
that overall, the three MPS genotypes progress with time.
Our observations were confirmed by TEM analysis that showed
an increased lysosomal burden and vacuoles, excess lipid storage,
and dense cytoplasm in MPS cerebral cortex compared to WT.
Furthermore, many more dystrophic axons containing autophagic
organelles and storage material were present in the MPSIIIB brain
compared to MPSI mice but none were detected in the MPSIIIA
brain regions we analysed. These dystrophic axons were similar to
those found in MPSIIIA mice by others [22] and in Alzheimer
disease (AD), another neurodegenerative disease [31]. The
dystrophic axons are comprised of vesicular organelles at various
stages of autophagocytosis and may aid in the removal of damaged
mitochondria so that initiation of apoptosis is avoided, resulting in
a protective effect [31,32].
Analysis of the disaccharide composition of HS from MPS
brains indicated that the HS in all MPS types was abnormally
highly sulphated compared to WT, with a trend for increased
sulphation from MPSI to IIIA, with IIIB the highest. This effect
was observed with a concomitant reduction in non- and mono-
sulphated disaccharides in MPS brain compared to WT. This
confirms our recently published work where significantly elevated
levels of sulphated disaccharides were detected in MPSI brain at 3
months of age [17]. Elevated N-sulphated HS disaccharide levels
have been found in MPSIIIA mouse brain compared to controls
using tandem mass spectrometry [18], thus our results also support
these observations. Furthermore, nuclear magnetic resonance and
tandem mass spectrometry have shown elevated levels of HS and
2-O-sulphation in MPSI and IIIA patient urine and serum, with
MPSIIIA exhibiting higher levels than MPSI [19,20]. Interesting-
ly, although the amounts of HS increased between MPSI and IIIA
mice, significantly less HS appeared to be stored in MPSIIIB
brains. This was surprising since MPSIIIB mice exhibited a
significantly larger lysosomal compartment compared to MPSI
and IIIA. The reason for this lower level of HS but larger
lysosomal compartment is unclear. It could be due to excess
storage of other materials such as cholesterol and other GM
gangliosides in MPSIIIB brain compared to MPSI and IIIA, since
GM2 ganglioside levels were similar in MPS brains. Alternatively,
it could be specific to the AMAC assay, whereby the type of HS
stored in MPSIIIB is not easily detected using this method or that
this assay is subject to variability. These possibilities are currently
under investigation.
The reasons why HS accumulation results in such severe brain
dysfunction remains to be explained. The various combinations of
N-, 6-O- and 2-O-sulphation modifications on HS are carried out
by the activity of sulphotransferase enzymes and enable HS to be
involved in many signalling processes. Highly sulphated HS is
likely to have altered growth factor/morphogen binding capacity,
increasing the binding of some factors while inhibiting the action
of others [15,33]. This may result in the persistence of any
abnormal downstream signalling. Recently we have found that
highly sulphated HS is responsible for changing one of the major
pathways in haematopoietic stem cell homing in MPSIH (Watson
et al unpublished data). Furthermore, we have shown that excess
HS in MPSI augments HS sulphation by positively enhancing the
sulphotransferase activity of N-deacetylase/N-sulphotransferase
enzymes in the Golgi [17]. Thus it is not unreasonable to predict
that excess HS in MPS diseases could play a significant role in
perturbing HS mediated signalling pathways in the brain, thus
perpetuating disease pathology.
It has been proposed that excess GAGs in the lysosome cause
secondary storage by inhibiting ganglioside degrading enzymes
[24,34]. GM2 and GM3 ganglioside storage has been shown in
mouse models of MPSI, IIIA, IIIB and VII [24]. We found that
significant GM2 ganglioside storage had already occurred by 4
months of age with no significant increase at 9 months. The low
level of residual enzyme activity (about 3–4% of WT) in the
MPSIIIA model [22] does not appear to have any effect on the
amount of gangliosides stored.
Since ganglioside storage is observed in the brains of patients
with MPSI and MPSIIIA [35,36] it has been proposed that
secondary storage may play a role in disease progression [37]. In
addition to the quantitative analysis of GM2 ganglioside
immunoreactivity in the cerebral cortex, we also observed very
intense GM2 ganglioside staining in other specific regions of the
brain. These areas were i) the amygdala, which is thought to be
responsible for memory and fear, ii) the lateral septal nucleus
which is related to the control of locomoter activity and stress, iii)
the thalamic and hypothalamic areas that direct and process
signals from the motor cortex, and iv) the preoptic area which is
involved in processing light and the circadian rhythm. McGlynn et
al also detected GM2 ganglioside staining in similar areas
including the cerebral cortex, amygdala, hippocampus and
retrospenial cortex [24]. It is tempting to speculate that excessive
GM2 gangliosidosis in these areas could contribute to behavioural
changes in MPSIIIA [28] and IIIB [38] mice, including
hyperactivity [28,38], reduced sense of danger [28] and altered
circadian rhythms [27,39] that we and others observe. Many of
the behavioural disturbances observed in mouse models of MPS
correlate well with those in patients but it is also possible that other
neuropathological factors are responsible for these observed
behaviours.
A high level of neuroinflammation was reached by 4 months of
age in all MPS mouse models, suggesting that this process starts
early in life, in agreement with findings in MPSIIIB [25] and
MPSIIIA brain [40]. Overall, astrocytosis was significantly higher
in MPS compared to WT and increases with time in all MPS
genotypes. Furthermore, astrocyte activation in MPSIIIA and IIIB
was significantly higher compared to MPSI. When multiple
comparisons were made between all genotypes at each timepoint,
astrocyte activation in MPSI was significantly slower to progress
compared to MPSIIIA and IIIB, but achieved similar levels by 9
months. However, microglial activation in MPSI mice was
significantly lower than MPSIIIA and IIIB at both 4 and 9
months. To support this data, we found that a number of
four sections of brain (Bregma 0.26,20.4621.18 and21.94 mm) and analysed (C). Four sections of brain (Bregma 0.26,20.4621.18 and21.94 mm)
were stained for Nissl substance (B) and two low power fields of view, covering cortical layers II/III–VI (boxed areas in A), were captured from each
section and the number of Nissl positive cells were counted using ImageJ (D). n = 3 mice per group, error bars represent the SEM and p values are
from two way ANOVA with Tukey’s multiple comparisons test. Significant individual genotype*time differences are shown by a thin green line.
Bar = 100 mm.
doi:10.1371/journal.pone.0035787.g007
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Figure 8. Significantly reduced levels of VAMP2 and Homer-1 and a change in the localisation of VAMP2 in MPS mouse cerebral
cortex. Representative images of low (cerebral cortical layers II/III–VI) and high power sections (cerebral cortical layers II/III) of VAMP2 (A) and Homer-
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inflammatory cytokines associated with monocyte/macrophage
(MIP-1a, MCP-1) and neutrophil (IL-1 a) recruitment to sites of
inflammation were significantly elevated in MPS brains compared
to WT. Furthermore, in MPSIIIB brain there was a significant
increase in KC, also involved in neutrophil recruitment and G-
CSF, which is involved in stimulation and proliferation of cells
from the haematopoietic lineage. HS has been shown to play a
major role in inflammation [41] and a number of studies have
observed neuroinflammation in MPSI, IIIA and IIIB mouse
models [21,23,25]. The elevated levels of highly sulphated HS that
we have detected may be responsible for neuroinflammation.
However, Ausseil et al have shown that in MPSIIIB mice deficient
in Toll-like receptor 4 (TLR4), neurodegeneration can occur
independently of microglial activation by HS, demonstrating that
inflammation via this pathway is not responsible for the majority of
pathology observed [21].
To further understand the cause of the neurodegeneration, we
measured the cerebral cortex thickness and counted the number of
neurons in specific areas of the cerebral cortex. A significant
reduction in neuronal cell numbers was observed in MPSIIIA
mice between 4–9 months, although no overall significant changes
were observed between MPS and WT brains, thus casting doubt
on the validity of this result. Vitry et al have also observed no
significant changes in neuronal cell number or cerebral cortical
thickness in MPSIIIB mouse brain compared to controls at 8
months of age [26]. It is possible that neuronal loss occurs at a later
time point in mouse models of MPS compared to patients.
We detected a significant reduction in the level of VAMP2, but
no change in the level of synaptophysin. These are synaptic vesicle
associated membrane proteins involved in docking of vesicles at
the pre-synaptic membrane, which forms part of the SNAP/
SNARE complex, before neurotransmitter substance is released
across the synapse allowing neurotransmission. VAMP2 staining
was disorganised compared to WTs suggesting that the formation
of synaptic vesicles or vesicle recycling may be disrupted by the
increase in the lysosomal compartment and/or the defect in
autophagy reported [42] in MPSIIIA. We have previously
reported reduced and mislocalised VAMP2 staining in the
suprachiasmatic nucleus of MPSIIIB mice [27]. VAMP2 knockout
mice are not viable, but cells cultured from knockout embryos
exhibit a defect in vesicle release [43]. Vitry et al detected a
reduction in the level of synaptophysin in cerebral cortex layer I
and II and overall, but no differences were observed in layers III,
V and VI [26] which were more similar to the areas examined in
1 (D) stained sections at 9 months of age (9 m). WTs exhibit discrete VAMP2 punctate staining (A; white arrows) which is lost in MPSI, IIIA and IIIB
mouse brain. Bar = 100 mm. Four sections of brain (Bregma 0.26, 20.46 21.18 and 21.94 mm) were stained concurrently for VAMP2 (B),
synaptophysin (C) and Homer-1 (E) and images of two low power fields of view covering cortical layers II/III–VI (boxed areas, Figure 1A) were captured
from each section and quantified using ImageJ (n = 3 mice per group). Error bars represent the SEM and p values are from two way ANOVA with
Tukey’s multiple comparisons test. Significant overall genotype differences are denoted by thick black lines and individual genotype*time differences
are shown by thin green lines. The significant individual genotype*time differences (p,0.001) between all MPSs and WT at each time point are not
shown for clarity.
doi:10.1371/journal.pone.0035787.g008
Table 1. Summary of MPS comparative neuropathology.
Genotype/Age WT 4 m WT 9 m MPSI 4 m MPSI 9 m MPSIIIA 4 m MPSIIIA 9 m MPSIIIB 4 m MPSIIIB 9 m
LAMP2 * 0.42 0.35 1.75 2.27 2.13 2.59 2.89 3.67
HS – % NAc ND 58.4 ND 41.5 ND 37.5 ND 32.8
HS – % NS ND 42.2 ND 58.5 ND 62.5 ND 66.6
HS – % 6S ND 20.8 ND 29.9 ND 31.4 ND 34.4
HS – % 2S ND 20.7 ND 44.2 ND 51.8 ND 55.4
Total HS (relative
to WT)
ND 1 ND 15.5 ND 25.8 ND 5.6
GM2 Ganglioside* 2.2 4.2 22.3 25.1 27.3 27.5 27.4 27.8
GFAP (No) 4 5 72 105 106 116 100 115
Isolectin B4 (No) 1 3 117 126 129 148 132 141
MIP-1a (pg/mg) ND 0.8 ND 4.5 ND 7.3 ND 7.4
MCP-1 (pg/mg) ND 0.5 ND 3.8 ND 4.45 ND 4
IL-1a (pg/mg) ND 0.03 ND 0.09 ND 0.12 ND 0.12
KC (pg/mg) ND 0.03 ND 0.07 ND 0.05 ND 0.2
IL-6 (pg/mg) ND 0.023 ND 0.008 ND 0.004 ND 0.011
G-CSF (pg/mg) ND 0.01 ND 0.03 ND 0.06 ND 0.11
Cortical Thickness
(mm)
871 911 933 929 887 852 940 869
Nissl (No) 922 1104 993 945 1207 904 1060 950
VAMP2 * 10.2 11.4 7.2 5.6 8.6 5.9 8 6.6
Synaptophysin* 114 107 104 111 110 111 115 102
Homer* 200 199 189 185 190 187 ND 190
*denotes arbitray units; ND denotes not determined; No denotes number.
doi:10.1371/journal.pone.0035787.t001
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this study (ie II/III–VI). Vitry et al also detected no differences in
the level of VAMP in 8 month old MPSIIIB brains compared to
WT. However, it was not stipulated whether they were detecting
VAMP1 or 2 and there may be differences in areas of the cerebral
cortex that were analysed [26].
Furthermore, we also detected a reduction in the level of
Homer-1 in MPS mouse brain. Homer-1 is a scaffold protein
enriched at post synaptic density of excitatory synapses where it
binds glutamate receptors and allows targeting of downstream
signaling through various pathways [44]. A reduction in Homer-1
may have downstream consequences on organisation and
signaling at the post-synaptic density that may cause a defect in
synaptic strength. Homer-1 knockout mice are viable but they
display behavioural and neuronal defects [45,46] and Homer
signalling is found to be altered in several neurological disorders
such as Schizophrenia, Alzheimer’s disease, neuropathic pain,
epilepsy and Fragile X syndrome [47]. It is evident that MPS
patients exhibit progressive mental decline, behavioural difficul-
ties, failure to reach developmental milestones and learning/
memory deficits that may be due in part to degeneration of the
synapse at the pre- and post-synaptic density.
What drives MPS disease progression still remains unclear.
Many of the neuropathological measures progress from 4 to 9
months, albeit relatively slowly. However, this assumes that all
MPS genotypes analysed here behave in a similar fashion. Thus,
significant disease specific changes over time are only seen in
MPSIIIB with lysosomal storage, MPSI with astrocyte activation
and MPSIIIA with microgliosis and cortical neuronal loss whilst
secondary pathology of GM2 appears to rapidly reach a threshold
at 4 months in all diseases. To elucidate the progressive
relationship between individual pathologies in each disease in
more detail, earlier timepoints and greater mouse numbers would
be required. It is clear that substantial pathology is already present
in all genotypes by 4 months of age and despite progression in
many factors the lack of overall change in cortical thickness and
neuronal cell number, suggests that substantial neuronal damage
has not yet occurred in mouse models of any of these diseases at
either 4 or 9 months, despite clear behavioural abnormalities
observed by us in MPSIIIA [28] and IIIB mice [38] by this age.
Incidentally, behavioural abnormalities are much less established
in both these models at 4 months of age, suggesting that disease
progression is ongoing. Overall, in MPSI there appears to be less
severe pathology in several parameters (the level of 2-O HS
sulphation, lysosomal compartment size, astrocyte activation and
microgliosis) and disease progression to similar threshold values as
MPSIIIA and IIIB from 4 to 9 months, suggesting that MPSI may
have less severe overall neuropathology than MPSIIIA or IIIB, at
least at these ages.
Neuroinflammation and neurodegeneration co-exist in a
number of other brain degenerative lysosomal storage disorders
[48,49,50] but it not known whether inflammation is a cause or
consequence of neurodegeneration. It has been shown in a mouse
model of multiple sclerosis, that prolonged exposure to TNF-a
from microglia, for example, can cause degeneration of the
synapse [51]. It is likely that in MPS diseases a combination of
factors are responsible for neurodegeneration. The amount and
length of exposure to different factors, as well as functional
inhibition of cellular pathways are doubtless interlinked in these
complex disorders. Aberrant biological activity of highly sulphated
HS, prolonged inflammation, storage material affecting autophagy
and other important cell functions such as synaptic vesicle
trafficking, and potentially other unknown factors could all be
combining to play a role in neurodegeneration.
In conclusion, we have evaluated and established baseline levels
of a number of neuropathological markers of MPS disease that can
be used as outcome measures for assessing new therapeutic
strategies. The differences in severity of neuropathological events
from MPSI to MPSIIIA and IIIB may have implications for the
level of treatment required to correct the neuropathology
observed.
Methods
Mouse maintenance and tissue collection
The mice used in this study were bred from heterozygotes,
maintained on a C57BL/6J background and housed in a 12/
12 hour light/dark cycle with food and water provided ad libitum in
accordance with the Animal (Scientific Procedures) Act, 1986
(UK), project licence PPL 40/3056 and approved by the
University of Manchester Ethical Review Process Committee.
The MPSI and MPSIIIB mouse models are knockouts generated
by targeted disruption of exon 6 in the Idua and Naglu genes
respectively [52,53]. The MPS IIIA mouse model is a spontane-
ously occurring mutant that retains around 3–4% of wild-type
(WT) levels of SGSH activity [54]. WTs used in the study were a
mixture of littermate controls from the 3 colonies and were a mix
of males and females randomised between ages and genotypes.
WT and MPS mice were sacrificed by cervical dislocation at 4 and
9 months of age. The brains were removed and either snap frozen
and stored at 280uC for biochemical analysis or fixed in 4%
paraformaldehyde in PBS for 24 hours at 4uC followed by
cryopreservation in 30% sucrose, 2 mM MgCl2 in PBS for
48 hours at 4uC before storing at 280uC for histological analysis.
Immunohistochemistry
Brain sections (30 mm) were cut using a freezing sledge
microtome (Hyrax S30, Carl Zeiss, Hertfordshire, UK) and each
section was stored in sequential wells of a 96 well plate for
identification. Free floating immunohistochemistry was performed
on sections taken from Bregma 0.26, 20.46 21.18 and
21.94 mm according to the mouse brain atlas [55] and each
subsequent antibody used the next adjacent set of comparative
sections. Sections for each antibody were all stained on the same
day using the same batch of solutions for each stain (n = 3 mice per
group). Staining with antibodies against LAMP2 (developed by
August, JT, Developmental Studies Hybridoma Bank, University
of Iowa, USA), GFAP (1:500; DakoCytomation, Ely, UK),
VAMP2 (1:500; Millipore, Watford, UK), synaptophysin (1:200;
Synaptic Systems, Gottingen, Germany) and Homer-1 (1:2000;
Synaptic Systems) were performed using the staining protocol as
previously described [8,27]. The microglia/macrophage staining
was performed using peroxidase conjugated isolectin B4 from
Bandeiraea simplicifolia (ILB4; Sigma, Poole, UK) as previously
described [6,27]. GM2 antibody (a gift from Dr Kostantin
Dobrenis and Prof Walkley) staining was also performed as
previously described [8,24]. For LAMP2 and GM2 staining Nickel
ions were included in the DAB substrate to produce a black stain
for easier quantification. Sections were mounted onto positively
charged slides (Fisher Scientific, Loughborough, UK) followed by
clearing and mounting in DPX medium (Fisher Scientific). GFAP
and ILB4 staining stained sections were counterstained with
Mayer’s haematoxylin before mounting.
For free floating immunofluorescent staining, sections were
blocked with 10% goat serum, 1% Triton X-100, 1 mg/ml BSA in
TBS for 1 hour at RT. Sections were incubated overnight at 4uC
with LAMP2 and Alexa-594-labelled ILB4 or NeuN (Neuronal
nuclei; Millipore, UK) diluted in blocking buffer. For ILB4
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staining, 1 mM MgCl2 and CaCl2 were added to the buffers.
Sections were washed 4 times with TBS and incubated with
secondary antibodies, diluted 1:1000 in blocking buffer, for 1 hour
at RT (Alexa 594-goat anti-mouse IgG and Alexa 488-goat anti-
rat IgG [1:1000; Invitrogen, Paisley, UK]), followed by 300 nM
DAPI (Invitrogen) for 15 minutes. Sections were washed with TBS
(64) and mounted onto positively charged slides with ProLong
Gold Antifade mounting medium (Invitrogen). Sections were
visualised using a Nikon C1 confocal on an upright 90 i
microscope with a 606/1.40 Plan Apo objective (Nikon Instru-
ments Europe B.V., Kingston, UK).
Image analysis
Four sections from each mouse brain (n = 3 mice per group),
were imaged as follows. Two non-overlapping fields of view
covering cerebral cortical layers II/III–VI per section were imaged
using an Axioscop light microscope and Axiocam color CCD with
Axiovision software (Carl Zeiss, Hertfordshire, UK) using the620
objective as shown in Figure 1A and 7A. The first image was taken
by lining up the base of the field of view with the edge of the
corpus callosum with the left edge in line with the apex of the
cingulum so that the cortical layers were running in a horizontal
direction. The second field of view was adjacent to the first field of
view. These areas equate to the primary motor, somatosensory
and parietal cortex. The observer was blinded to genotype and
age. Images for each stain were all taken at the same exposure
settings and in the same session. To quantify the antibody staining,
the images were converted to 8 bits of grey resolution, saved in the
TIFF format for analysis using Image J software (NIH, USA). For
LAMP2 and GM2 staining, an unstained area was used to subtract
background staining from each unmanipulated image. For each
stain an average of the levels of optical density was calculated from
8 fields of view per mouse. The number of GFAP, ILB4 and Nissl
positive cells were counted per image totalling 8 fields of view per
mouse to produce an average number of cells per mouse. Nissl
stained sections were also scanned using the Pannoramic SCAN,
(Laser 2000 (UK), Ringstead, UK) and Laser2000 software was
used to measure the cortical thickness. The first measurement was
taken from the apex of the cingulum of the corpus callosum and
the distance was measured to the outside of cerebral cortical layer
II. The second measurement was taken from a point 1,000 mm
laterally from the apex of the cingulum and the distance from the
corpus callosum to the outside of cerebral cortical layer II was
measured.
Transmission Electron Microscopy
At 8–9 months of age, WT, MPSI, MPSIIIA and MPSIIIB mice
(n = 3 mice per group) were transcardially perfused under
anaesthesia (0.079 mg/ml fentanyl, 2.5 mg/ml fluanisone,
1.25 mg/ml midazolam) with Tyrode’s buffer (138 mM NaCl,
1.8 mM CaCl2, 0.3 mM NaH2PO4, 5.6 mM glucose, 12 mM
NaHCO3, 2.7 mM KCl, pH 7.4) followed by fixative (4%
paraformaldehyde, 2% gluteraldehyde in 100 mM sodium
cacodylate buffer pH 7.2–7.4). Brains were removed and placed
in the same fixative for 1–2 hours at 4uC. A 1 mm coronal section
was taken 3 mm from Bregma 2.8 and divided into 2 hemispheres
using a mouse brain matrix. From the midline, a section of cortex
(around 2 mm63 mm) was taken from the corpus callosum up to
the outside edge of the cerebral cortex was removed and processed
as follows. Samples were washed for 5 minutes in 100 mM sodium
cacodylate buffer and post-fixed in reduced osmium (1%
OsO4+1.5% K4Fe(CN)6) in 100 mM sodium cacodylate buffer
pH 7.2–7.4 for 1 hour at RT. Samples were incubated in 1%
tannic acid in 0.1 M cacodylate buffer pH 7.2 for 1 h and in 1%
uranyl acetate in water at RT for 1 hour followed by dehydration
through an ethanol series (25%, 50%, 70%, 90% ethanol
10 minutes each) and absolute ethanol for 20 mins with 3 further
changes (30 mins each). Samples were infiltrated with 50% TAAB
LV resin/50% absolute alcohol for one hour, with 1 part absolute
alcohol and 3 parts TAAB LVresin overnight then three fresh
changes of 100% resin throughout the following day. Samples
were embedded in fresh resin and polymerised at 60uC overnight.
Sections (70 nm) were cut using Reichert Ultracut S ultramicro-
tome and visualised using a FEI Tecnai 12 Biotwin Transmission
Electron Microscope at 80 kV acceleration voltage. Images were
captured using a Gatan Orius SC1000 camera. Whole sections
were assessed for gross morphological differences with an
independent observer (n = 3 mice per group).
Biochemical analysis of HS
Since a larger amount of starting material is required for this
technique, one hemisphere of brain from 8–9 month old MPSI,
MPSIIIA and MPSIIIB mice was used for HS biochemical
analysis (n = 3 mice per group). Brain samples were disaggregated
mechanically in PBS and treated essentially as described
previously [17]. Briefly, tissues were pronase treated before GAGs
were purified using a DEAE-sephacel column. Following desalting
HS chains were digested into their component disaccharides using
a combination of bacterial heparinases I, II and III enzymes.
Resultant disaccharides were labelled with 2-aminoacridone
(AMAC) and separated by RP-HPLC as described by Deakin
and Lyon, applying the quoted disaccharide labelling efficiency
factor during relative quantification [29]. Duplicate heparinase-
digestions followed by RP-HPLC were performed per brain.
Integration analysis of disaccharide peak-areas enabled relative
quantification of HS amounts and disaccharide composition to be
calculated. The percentage of total disaccharides containing either
an N-acetylated or N-sulphated glucosamine, or containing 6-O-
sulphation of GlcNAc or GlcNS or 2-O-sulphation of IduA or
GlcA was also calculated from disaccharide compositions analyses,
by summing the total number of disaccharides with that
modification. An additional AMAC-labelled peak, that does not
correspond with any known heparinase generated disaccharide
was visible on the HPLC trace in MPSIIIA brain HS samples, at a
unique location to the HS end structure previously identified in
MPSI samples [17]. However due to its unknown structure it was
excluded from disaccharide compositional calculations.
Cytometric Bead Array
The levels of IL-1a, IL-1b, IL-3, IL-6, IL-9, IL-13, IFN-c,
MCP-1, MIP-1a, G-CSF, GM-CSF and KC (or CXCL1) were
measured in whole brain extracts of 8–9 month old WT, MPSI,
IIIA and IIIB mice (n = 5–6 per group) using BD Cytometric Bead
Array (CBA) Flex Set kits (BD Biosciences, Oxford, UK). One
hemisphere was homogenised in homogenisation buffer (250 ml;
50 mM Tris-HCl, 150 mM NaCl, 5 mM CaCl2, 0.02% NaN3,
1% Triton X-100, protease inhibitors, pH 7.4) using an electric
homogeniser. Samples were centrifuged at 17,000 g at 4uC for
30 minutes and the supernatant used immediately in the CBA
assay. A mix of standard beads for each flex set was reconstituted
in Assay Diluent, to make a serial dilution for the standard curve
(10–2500 pg/ml). The capture beads (0.2 ul per test) were mixed
together in capture bead diluent (10 ul per test). The PE detection
reagents (0.2 ul per test) were mixed together in detection reagent
diluent (10 ul per test) and stored at 4uC in the dark until used.
The mixed capture beads were mixed in an equal volume (10 ul)
with standard or sample in FACS tubes (BD) and incubated at
room temperature for 1 hour. This was followed by addition of
MPSI, IIIA and IIIB Neuropathology
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10 ul mixed detection reagent, and incubation at room temper-
ature for 1 hour in the dark. Wash buffer was added and the
samples centrifuged at 200 g for 5 minutes. The beads were
resuspended in 200 ul wash buffer and vortexed before analysis on
the flow cytometer (FACS Canto II, BD). The singlet bead
population was identified on a FSC vs SSC plot, then the
individual beads were separated using APC and APC-Cy7 and the
level of each cytokine was measured on PE. 300 events were
recorded per analyte, using the singlet population as the storage
gate and stopping gate. The results were exported and analysed
using FCAP Array software (BD). The protein concentration of the
samples was measured using the BCA assay and the cytokine levels
were standardised to protein level for each sample.
Statistical analysis
All data was analysed using two way ANOVA with Tukey’s
multiple comparisons test to determine the differences between
each group using JMP software (SAS Ltd, UK) except for the HS
and CBA cytokine analysis which was analysed by one way
ANOVA with Tukey’s multiple comparisons test using SPSS
software. Where significant genotype*time effects were seen in 2
way ANOVA, we established that WT was the genotype behaving
differently to the MPS genotypes by performing a confirmatory 2
way ANOVA on time vs genotype for MPS genotypes alone. This
allowed us to confirm that MPS genotypes all progress over time
for some parameters.
Supporting Information
Figure S1 Lysosomal compartment size is significantly
increased in MPS brain and localises to neurons and
microglia. LAMP2 (green) was detected in NeuN-positive
neurons (red) and in ILB4-positive microglia (red) of layer II/III
of WT, MPSI, IIIA and IIIB cerebral cortex. Nuclei are stained
with DAPI (blue; Bar = 10 mm).
(TIF)
Figure S2 Significant astrocytosis in MPS cerebral
cortex at 4 and 9 months of age. Representative sections of
positively stained astrocytes (GFAP; brown) at 4 and 9 months of
age (4 m and 9 m) that correspond to a whole field of view used for
counting positive cells covering cortical layer IV (from section 2a,
Figure 1A). Sections were counterstained with Mayer’s haema-
toxylin to highlight the nuclei. Magnified sections are shown in
Figure 5A. Bar = 100 mm.
(TIF)
Figure S3 Significant microgliosis in MPS cerebral
cortex at 4 and 9 months of age. Representative sections of
positively stained microglia (ILB4; brown) at 4 and 9 months of
age (4 m and 9 m) that correspond to a whole field of view used for
counting positive cells covering cortical layer IV (from section 2a,
Figure 1A). Sections were counterstained with Mayer’s haema-
toxylin to highlight the nuclei. Magnified sections are shown in
Figure 5C. Bar = 100 mm.
(TIF)
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